Factor XI deficiency

Stefano Duga, Ophira Salomon

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Severe factor XI (FXI) deficiency is an injury-related bleeding disorder common in Ashkenazi Jews and rare worldwide. In the past two decades, more than 180 mutations in the FXI gene have been reported in patients with FXI deficiency, five of which show a founder effect (Cys38Arg, Gln88Stop, Cys128Stop, Glu117stop, and Phe283Leu, the last two largely prevalent among Ashkenazi Jews). Inhibitors to FXI after exposure to plasma, FXI concentrates, or Rh immunoglobulin were described in patients with mutations resulting in null alleles. Treatment with low-dose recombinant activated factor VII in these patients appears promising. Survival advantages to patients with severe FXI have been recently reported. Herein, we present new observations related to clinic presentation, genotype-phenotype correlation, and treatment problems in patients with FXI deficiency.

Original languageEnglish
Pages (from-to)416-425
Number of pages10
JournalSeminars in Thrombosis and Hemostasis
Volume35
Issue number4
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Factor XI Deficiency
Factor XI
Jews
Founder Effect
Factor VIIa
Mutation
Genetic Association Studies
Immunoglobulins
Alleles
Hemorrhage
Survival
Wounds and Injuries
Therapeutics
Genes

Keywords

  • Bleeding
  • CRM+
  • Factor XI
  • Founder effect
  • Inhibitors
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Factor XI deficiency. / Duga, Stefano; Salomon, Ophira.

In: Seminars in Thrombosis and Hemostasis, Vol. 35, No. 4, 06.2009, p. 416-425.

Research output: Contribution to journalArticle

Duga, Stefano ; Salomon, Ophira. / Factor XI deficiency. In: Seminars in Thrombosis and Hemostasis. 2009 ; Vol. 35, No. 4. pp. 416-425.
@article{7b0c30aa6fa8431ab021b493249bad91,
title = "Factor XI deficiency",
abstract = "Severe factor XI (FXI) deficiency is an injury-related bleeding disorder common in Ashkenazi Jews and rare worldwide. In the past two decades, more than 180 mutations in the FXI gene have been reported in patients with FXI deficiency, five of which show a founder effect (Cys38Arg, Gln88Stop, Cys128Stop, Glu117stop, and Phe283Leu, the last two largely prevalent among Ashkenazi Jews). Inhibitors to FXI after exposure to plasma, FXI concentrates, or Rh immunoglobulin were described in patients with mutations resulting in null alleles. Treatment with low-dose recombinant activated factor VII in these patients appears promising. Survival advantages to patients with severe FXI have been recently reported. Herein, we present new observations related to clinic presentation, genotype-phenotype correlation, and treatment problems in patients with FXI deficiency.",
keywords = "Bleeding, CRM+, Factor XI, Founder effect, Inhibitors, Treatment",
author = "Stefano Duga and Ophira Salomon",
year = "2009",
month = "6",
doi = "10.1055/s-0029-1225764",
language = "English",
volume = "35",
pages = "416--425",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Factor XI deficiency

AU - Duga, Stefano

AU - Salomon, Ophira

PY - 2009/6

Y1 - 2009/6

N2 - Severe factor XI (FXI) deficiency is an injury-related bleeding disorder common in Ashkenazi Jews and rare worldwide. In the past two decades, more than 180 mutations in the FXI gene have been reported in patients with FXI deficiency, five of which show a founder effect (Cys38Arg, Gln88Stop, Cys128Stop, Glu117stop, and Phe283Leu, the last two largely prevalent among Ashkenazi Jews). Inhibitors to FXI after exposure to plasma, FXI concentrates, or Rh immunoglobulin were described in patients with mutations resulting in null alleles. Treatment with low-dose recombinant activated factor VII in these patients appears promising. Survival advantages to patients with severe FXI have been recently reported. Herein, we present new observations related to clinic presentation, genotype-phenotype correlation, and treatment problems in patients with FXI deficiency.

AB - Severe factor XI (FXI) deficiency is an injury-related bleeding disorder common in Ashkenazi Jews and rare worldwide. In the past two decades, more than 180 mutations in the FXI gene have been reported in patients with FXI deficiency, five of which show a founder effect (Cys38Arg, Gln88Stop, Cys128Stop, Glu117stop, and Phe283Leu, the last two largely prevalent among Ashkenazi Jews). Inhibitors to FXI after exposure to plasma, FXI concentrates, or Rh immunoglobulin were described in patients with mutations resulting in null alleles. Treatment with low-dose recombinant activated factor VII in these patients appears promising. Survival advantages to patients with severe FXI have been recently reported. Herein, we present new observations related to clinic presentation, genotype-phenotype correlation, and treatment problems in patients with FXI deficiency.

KW - Bleeding

KW - CRM+

KW - Factor XI

KW - Founder effect

KW - Inhibitors

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=67749102041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67749102041&partnerID=8YFLogxK

U2 - 10.1055/s-0029-1225764

DO - 10.1055/s-0029-1225764

M3 - Article

C2 - 19598070

AN - SCOPUS:67749102041

VL - 35

SP - 416

EP - 425

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 4

ER -